Prestige Consumer Healthcare Inc. $PBH Shares Sold by Susquehanna International Group LLP

Susquehanna International Group LLP lowered its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 84.7% during the second quarter, Holdings Channel reports. The firm owned 6,876 shares of the company’s stock after selling 38,086 shares during the period. Susquehanna International Group LLP’s holdings in Prestige Consumer Healthcare were worth $325,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PBH. BlackRock Inc. purchased a new stake in Prestige Consumer Healthcare in the second quarter valued at $370,187,000. Dimensional Fund Advisors LP grew its stake in Prestige Consumer Healthcare by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock worth $158,414,000 after buying an additional 91,710 shares during the last quarter. State Street Corp increased its position in Prestige Consumer Healthcare by 1.4% during the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock worth $122,917,000 after buying an additional 27,721 shares during the period. Morgan Stanley grew its position in shares of Prestige Consumer Healthcare by 6.3% during the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after acquiring an additional 71,078 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Prestige Consumer Healthcare by 5.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after acquiring an additional 35,126 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on PBH. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Trading Up 2.1%

NYSE PBH opened at $52.85 on Wednesday. The stock has a market capitalization of $2.50 billion, a P/E ratio of 14.80, a P/E/G ratio of 1.62 and a beta of 0.33. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $71.07. The firm has a 50-day moving average price of $50.48 and a 200 day moving average price of $54.35. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The firm had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm’s revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).